“HGH peptides” is a marketing label for a group of drugs that share one goal: getting the pituitary gland to release more of the growth hormone it already makes. The label hides a real split. Half the group copies one natural signal and half copies another, and the regulatory status, the evidence and the risks differ molecule by molecule.
Are growth hormone peptides the same as HGH?
No. Human growth hormone (somatropin) is the hormone itself, given by injection so that the body receives it directly. A growth hormone peptide is a signal. It reaches the pituitary and prompts a release of your own hormone, in pulses, and the pituitary’s own feedback brakes stay in place. That difference has a practical edge: a secretagogue needs a pituitary that can still respond, which is why sermorelin’s mechanism does nothing for someone whose gland has been removed or damaged.
Even the longest-acting peptide in the group keeps the pulse pattern. In a 2006 study of CJC-1295, growth hormone kept arriving in pulses while the drug stimulated the receptor continuously [5]. The side-by-side detail of the two approaches, including cost and monitoring, is in the sermorelin vs. HGH comparison.
Which peptides release growth hormone, and how do the two classes differ?
GHRH analogs copy growth hormone-releasing hormone, the hypothalamic signal that tells the pituitary to release. Sermorelin is the first 29 amino acids of that hormone. Tesamorelin is the full 44-amino-acid sequence with a short six-carbon chain attached to its front end [8]. CJC-1295 is a modified 29-amino-acid version built to bind albumin in the blood; in healthy adults a single injection raised growth hormone 2- to 10-fold for six days or more, with an estimated half-life of 5.8 to 8.1 days [4].
Ghrelin mimetics act on a different receptor, the one the hunger hormone ghrelin uses (often written GHS-R). Ipamorelin, GHRP-2 and GHRP-6 are injected peptides. MK-677, also called ibutamoren, is technically not a peptide at all but a small molecule taken by mouth, and it is sold in the same breath; sermorelin vs. MK-677 sets the pill against the injection. Ipamorelin’s selling point dates to its first paper: in animal testing it released growth hormone without raising cortisol or ACTH, even at doses more than 200 times its effective dose, where GHRP-2 and GHRP-6 did raise them [3].
The two receptors sit on the same pituitary cells, which is the whole argument behind combining one of each. What a sermorelin and ipamorelin blend contains covers whether that pairing has ever been tested.
Which growth hormone peptides are FDA-approved in 2026?
One. The table reads FDA’s own documents: drug approvals, the Category 2 safety page as of the FDA page updated April 22, 2026, and the 503A and 503B nomination lists. “Category 2” is where FDA places bulk substances it says may present significant safety risks in compounding.
| Molecule | FDA status | Main human evidence |
|---|---|---|
| Sermorelin (GHRH analog) | Approved as Geref in 1990, since discontinued, not for safety reasons. Not on the Category 2 page. Compounded on prescription. | One adult trial, n = 19, 16 weeks |
| Tesamorelin (GHRH analog) | Approved (EGRIFTA SV, EGRIFTA WR) for excess abdominal fat in adults with HIV and lipodystrophy | Phase 3 trials, n = 412 and n = 404 |
| CJC-1295 (GHRH analog) | Never approved. Listed under “nominated but withdrawn” on the Category 2 page. | Hormone-level studies in healthy adults |
| Ipamorelin (ghrelin mimetic) | Never approved. Category 2 for outsourcing facilities (503B); its pharmacy-side (503A) nomination was withdrawn. | One bowel-surgery trial, n = 114 |
| GHRP-2, GHRP-6 (ghrelin mimetics) | Never approved in the US. Category 2 under 503B; nominated without adequate support under 503A. | Mostly hormone-response and diagnostic-test studies |
| MK-677 / ibutamoren (oral) | Never approved. Category 2 under both 503A and 503B. | One 2-year trial in older adults, n = 65 |
Sources for the table: Drugs@FDA for Geref [7], the EGRIFTA SV label [8], FDA’s Category 2 page [9], and the 503A and 503B nomination lists [10] [11]. The longer history of sermorelin’s approval is in whether sermorelin is FDA-approved, and what the April 2026 page changes did and did not mean is in sermorelin’s legal status in 2026.
Do growth hormone peptides actually work?
At raising growth hormone and IGF-1, yes, reliably, across both classes. That part is not in dispute. The harder question is whether the rise changes anything a person would notice, and there the record is uneven and specific to each drug.
- Tesamorelin has the strongest outcome data. In 412 adults with HIV, 26 weeks of daily injections cut visceral fat by 15.2% vs. a 5.0% increase on placebo, and IGF-1 rose 81.0% [2]. The population and the outcome are narrow: belly fat in HIV-associated lipodystrophy, not general fat loss.
- MK-677 raised fat-free mass by 1.1 kg against a 0.5 kg loss on placebo over a year in 65 healthy adults aged 60 to 81, and the extra lean mass did not change strength or function [6].
- Sermorelin rests on one 16-week trial in 19 adults aged 55 to 71. Lean body mass rose in the men and not in the women [1]. What that trial found is covered measure by measure.
- CJC-1295 has hormone-level data only: it raised growth hormone and IGF-1 in healthy adults [4], with no published body-composition or performance outcome.
- Ipamorelin was tested for one clinical use, bowel recovery after surgery, and missed: median time to a first tolerated meal was 25.3 hours vs. 32.6 hours on placebo, a difference the authors could not distinguish from chance (p = 0.15) [12].
So “do they work” has a different answer for each name on the bottle, and none of them has a trial measuring the outcomes most often advertised for them: muscle in younger adults, recovery, sleep or anti-aging.
What are the side effects of GH peptides?
The shared effects follow from the hormone. More growth hormone means fluid retention, joint and muscle aches, and some loss of insulin sensitivity. The tesamorelin label puts numbers on these: blood sugar reaching the diabetes range (HbA1c 6.5% or higher) in 5% vs. 1% on placebo, and injection-site reactions in 25% vs. 14% [8]. In the MK-677 trial, fasting glucose rose about 5 mg/dL, appetite increased, and mild leg swelling and muscle pain were the most common complaints [6].
Some risks are molecule-specific. FDA’s Category 2 entry for ibutamoren cites a hip-fracture trial stopped early for a possible heart-failure signal; its CJC-1295 entry notes reports of increased heart rate and a systemic vasodilatory reaction; and its entries for the injected ghrelin mimetics flag the risk of immune reactions to impurities [9]. Sermorelin’s own trial reported a transient rise in blood lipids as its only adverse effect [1], with the fuller picture in sermorelin’s side effects. Tesamorelin’s full warning list is in tesamorelin dosage and side effects.
Can you get growth hormone peptides prescribed legally?
Two of them, by different routes. Tesamorelin is a branded prescription drug, dispensed by pharmacies like any other approved medicine. Sermorelin is compounded: a licensed pharmacy prepares it to a prescription, and FDA’s 503B list files sermorelin acetate as a component of an FDA-approved drug [11]. A compounded drug is not reviewed by FDA before it reaches you, which is why knowing which pharmacy makes yours matters.
For the rest, coming off the Category 2 page does not put a substance on the list of what pharmacies may compound. Ipamorelin, CJC-1295 and the GHRPs are widely sold as “research chemicals” labeled not for human use, which is a different product category with different risks, set out in prescribed vs. research-chemical sermorelin.
Which growth hormone peptide is best?
No trial has compared them head to head, so “best” has no evidence-based answer. They answer different questions. Tesamorelin is the only one with an approved use and phase 3 outcome data, for a specific condition. Sermorelin is the one most readily prescribed for general adult use, on thin evidence. The others are either unapproved, under safety review, or both. The pairwise detail is in the sermorelin vs. tesamorelin, sermorelin vs. ipamorelin and sermorelin vs. CJC-1295 comparisons, and the three most-asked-about side by side in sermorelin vs. tesamorelin vs. ipamorelin.